AMLX · Amylyx Pharmaceuticals Inc.
The AI's read
Amylyx posted positive Phase 3 LUCIDITY topline results for avexitide, meeting the FDA-agreed primary endpoint and cutting Level 2/3 hypoglycemic events by 55%. That moves the program from hopeful to real regulatory trajectory and supports an NDA push toward a 2027 launch. The market already reacted hard, with the stock up about 33% and sitting near its 52-week high, so a lot of immediate upside is priced. There is still upside if the FDA pathway and label stay clean, but the short-term asymmetry is smaller than before the print. Our take is cautiously bullish: the clinical readout is high-quality company-specific news, yet macro and the big intraday pop reduce near-term optionality. We’d keep conviction moderate and watch for NDA details, label framing, and any emerging safety signals.